In vitro release and in vitro–in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles

Figures & data

Figure 1 Images of (A) TEM image for solid silica nanoparticles, (B) TEM image of empty HMSNs, and (C) TEM image of silybin meglumine-loaded HMSNs.

Abbreviations: HMSNs, hollow-type mesoporous silica nanoparticles; TEM, transmission electron microscopy.

Figure 2 Nitrogen adsorption–desorption isotherms of solid silica nanoparticles (◆), empty HMSNs (▴), and silybin meglumine-loaded HMSNs (■). Figure 2 insert: line (A) represents empty HMSNs, line (B) represents silybin meglumine-loaded HMSNs, and line (C) represents solid silica nanoparticles.

Abbreviation: HMSNs, hollow-type mesoporous silica nanoparticles.

Figure 3 In vitro release curves of silybin from different formulations in various dissolution media. (A) In vitro release curves of silybin meglumine-loaded hollow-type mesoporous silica nanoparticles in artificial gastric juice (■) and artificial intestinal juice (▴); (B) in vitro release curves of silybin meglumine-loaded hollow-type mesoporous silica nanoparticles in Na₂CO₃ solutions with different concentrations [0.1 M (line A), 0.08 M (line B), 0.06 M (line C), and 0.01 M (line E)], and in 0.01 M NaOH solution (line D); (C) in vitro release curves of silybin meglumine-loaded solid silica nanoparticles in artificial gastric juice (■) and artificial intestinal juice (▴).

Note: Each datum point represents the mean ± standard deviation of three administrations.

Table 1 Mean plasma concentration-time data for silybin meglumine-loaded incorporated into hollow-type silica nanoparticles following a single dose

Time points (hours)	Mean plasma concentration of silybin (ng/mL)	Standard deviationa
0.25	104.03	8.28
0.5	129.31	8.15
1	147.31	7.11
2	180.97	4.50
4	203.38	4.90
6	254.55	19.47
8	283.00	12.47
10	312.10	14.15
12	323.90	7.03
16	321.79	11.37
24	324.76	14.36
36	271.03	14.93
48	253.09	7.66
60	209.13	18.45
72	110.17	8.29

Note:

a Both positive and negative standard deviations were included.

Figure 4 In vivo absorption fraction of silybin meglumine-loaded hollow-type mesoporous silica nanoparticles generated from the Wagner–Nelson method.

Figure 5 Correlations between in vitro dissolution fractions and in vivo absorption fractions. (A) IVIVC of silybin meglumine-loaded HMSNs in artificial gastric juice; (B) IVIVC of silybin meglumine-loaded HMSNs in artificial intestinal juice; (C) IVIVC of silybin meglumine-loaded HMSNs in 0.06 M Na₂CO₃ solution; (D) IVIVC of silybin meglumine-loaded HMSNs in 0.08 M Na₂CO₃ solution; and (E) IVIVC of silybin meglumine-loaded HMSNs in 0.1 M Na₂CO₃ solution.

Abbreviations: HMSNs, hollow-type mesoporous silica nanoparticles; IVIVC, in vitro–in vivo correlations.